Mohty, M., Socie, G., Szer, J., Niederwieser, D., Butler, J., Wagner-Drouet, E., Or, R., Rovenvald-Zuckerman, T., Bozdag, S. C., Forcade, E., Grillo, G., Kröger, N., Stölzel, F., Russo, D., Sanz, J., Sarkar, R., Stefanelli, T., Wilke, C., Zeiser, R., Bubnoff, N. V. (2025). Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00809